PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

Showing 44 from 1 topic.Sort: Newest | Oldest
Vancomycin Trough Near 15.9 mg/L Flags Nephrotoxicity Risk
Analysis Pharmacokinetics / TDM Confirmatory Grade: Low
Also in Infectious Disease / Antimicrobials, Nephrology

Vancomycin trough over 15.9 mg/L linked to kidney injury.

Terlipressin Linked to Lower In-Hospital Mortality in HRS-AKI
★ Editor's Pick Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Very Low
Also in Gastroenterology / Hepatology

Terlipressin shows promise in lowering HRS-AKI mortality compared to standard treatments.

Positive Fluid Balance Linked to Severe AKI in Surgical ICU
Analysis Critical Care / ICU Hypothesis-generating Grade: Very Low
Also in Nephrology

Fluid overload post-surgery may increase severe acute kidney injury risk.

Tirzepatide Cuts Major Kidney Events 23% Versus Dulaglutide in SURPASS-CVOT
Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Moderate

Tirzepatide outshines dulaglutide in kidney protection for diabetes.

International Hypertension Guidelines in CKD: ESH, ESC, KDIGO, and AHA/ACC Compared
Guideline Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Also in Cardiology

Navigating global hypertension guidelines in CKD can enhance patient care.

Dual NSAID Analgesia After Robotic Renal Surgery Shows No AKI Signal
Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Low
Also in Perioperative / Anesthesia

Adding acetaminophen/ibuprofen to ketorolac PCA is safe for kidneys post-renal surgery.

Pharmacist Review Flags Drug Problems in CKD Patients Starting SGLT2 Inhibitors
Analysis Ambulatory Care / MTM Hypothesis-generating Grade: Very Low
Also in Nephrology, Medication Safety

Pharmacist interventions reduce drug problems in CKD patients on SGLT2 inhibitors.

KDIGO Consensus Reframes Kidney-Heart Failure Comanagement Priorities
Analysis Oncology Pharmacy Confirmatory Grade: Low
Also in Nephrology

Preventing kidney damage in cancer treatment requires proactive strategies.

INFINITY: Finerenone Benefits Extend to Non-Diabetic Chronic Kidney Disease
★ Editor's Pick Analysis Nephrology / Renal Pharmacy Practice-changing Grade: Moderate

Finerenone cuts kidney decline risk by nearly a quarter.

New AHA/ACC/ADA/ASN Guideline Unifies Cardiovascular-Kidney-Metabolic Syndrome Management
★ Editor's Pick Guideline Cardiology Practice-changing Grade: High
Also in Nephrology, Endocrinology / Obesity

New guideline integrates cardiovascular, kidney, and metabolic care.

KDIGO Consensus Reframes Kidney Function Changes in Heart Failure
Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Low
Also in Cardiology

CKD and HF coexistence demands integrated management strategies.

Active Pharmacist Ward Integration Outperforms Education in Renal Prescribing
Analysis Medication Safety Hypothesis-generating Grade: Low
Also in Nephrology

Pharmacist interventions cut drug-related issues by 30% in renal patients.

Finerenone Slows eGFR Decline in Non-Diabetic CKD
Analysis Nephrology / Renal Pharmacy Practice-changing Grade: Moderate
Also in Cardiology

FIND-CKD extends the kidney-protective role of finerenone from diabetic to non-diabetic chronic kidney disease, giving pharmacists a new evidence-based add-on to renin-angiotensin system blockade.

KDIGO 2024 Chronic Kidney Disease Guideline: Precision CKD Care for Pharmacists
Guideline Nephrology / Renal Pharmacy Practice-changing Grade: Moderate

The 2024 KDIGO guideline for CKD introduces new recommendations for screening, diagnosis, risk stratification, pharmacologic intervention, and bone-mineral disorder, with significant implications for pharmacist monitoring roles.